Amoeba SA (ALMIB) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.644x

Based on the latest financial reports, Amoeba SA (ALMIB) has a cash flow conversion efficiency ratio of 0.644x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.45 Million ≈ $-4.04 Million USD) by net assets (€-5.36 Million ≈ $-6.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALMIB defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Amoeba SA - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Amoeba SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Amoeba SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Amoeba SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Hindustan Media Ventures Limited
NSE:HMVL
0.012x
TETHYS PETROLEUM LTD
F:TP21
0.112x
Akme Fintrade India Ltd
NSE:AFIL
-0.209x
Ramssol Group Bhd
KLSE:0236
0.028x
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
0.018x
Vow ASA
OL:VOW
0.300x
Clime Capital Ltd
AU:CAM
-0.045x
International Media Acquisition Corp
NASDAQ:IMAQ
0.023x

Annual Cash Flow Conversion Efficiency for Amoeba SA (2012–2025)

The table below shows the annual cash flow conversion efficiency of Amoeba SA from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Amoeba SA worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €-5.36 Million
≈ $-6.27 Million
€-6.13 Million
≈ $-7.16 Million
1.143x +182.19%
2024-12-31 €-10.41 Million
≈ $-12.17 Million
€-4.22 Million
≈ $-4.93 Million
0.405x -75.44%
2023-12-31 €-3.94 Million
≈ $-4.61 Million
€-6.50 Million
≈ $-7.60 Million
1.649x +349.19%
2022-12-31 €8.16 Million
≈ $9.54 Million
€-5.40 Million
≈ $-6.32 Million
-0.662x +97.77%
2021-12-31 €198.68K
≈ $232.28K
€-5.90 Million
≈ $-6.90 Million
-29.704x -1727.93%
2020-12-31 €2.00 Million
≈ $2.34 Million
€-3.25 Million
≈ $-3.80 Million
-1.625x -89.00%
2019-12-31 €4.23 Million
≈ $4.94 Million
€-3.64 Million
≈ $-4.25 Million
-0.860x +12.73%
2018-12-31 €5.41K
≈ $6.33K
€-5.33K
≈ $-6.23K
-0.985x -142.87%
2017-12-31 €12.52K
≈ $14.64K
€-5.08K
≈ $-5.94K
-0.406x -32.43%
2016-12-31 €18.63K
≈ $21.78K
€-5.71K
≈ $-6.67K
-0.306x +22.04%
2015-12-31 €10.60K
≈ $12.39K
€-4.16K
≈ $-4.87K
-0.393x +7.81%
2014-12-31 €2.80 Million
≈ $3.27 Million
€-1.19 Million
≈ $-1.39 Million
-0.426x -136.98%
2013-12-31 €433.99K
≈ $507.38K
€500.21K
≈ $584.79K
1.153x +771.59%
2012-12-31 €947.20K
≈ $1.11 Million
€-162.56K
≈ $-190.04K
-0.172x --

About Amoeba SA

PA:ALMIB France Agricultural Inputs
Market Cap
$68.48 Million
€58.57 Million EUR
Market Cap Rank
#20754 Global
#325 in France
Share Price
€0.75
Change (1 day)
-1.05%
52-Week Range
€0.75 - €1.16
All Time High
€38.22
About

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopath… Read more